Insights · Signals for the decisions ahead

Clarity for the edge of science and capital.

Analysis for leaders navigating therapeutic complexity, operating constraints, and the commercial choices that connect them.

Read the latest analysisBrowse the archive
03Latest analyses
02Years of archive
73Published perspectives

Latest analysis

A sharper view of the decision ahead.

Independent analysis from Lonrú Consulting, spanning scientific, commercial, regulatory, and operating questions.

AI and governed systems

5 August 2026

The Valuation Engine: Defending Asset Worth with Dynamic Intelligence

A decision-support environment that helps technology transfer and academic teams test valuation assumptions with the relevant evidence in view.

Read the analysis

AI and governed systems

29 July 2026

Frictionless Due Diligence: The Automated Data Room

A governed diligence environment can make evidence easier to retrieve, review, and explain when complex questions arrive.

Read the analysis

AI and governed systems

24 July 2026

The $50k Compute Catalyst: What Anthropic’s Rare Disease Grants Actually Signal

Anthropic recently announced a call for their AI for Science rare disease research grants, offering up to $50,000 in Claude API credits to researchers exploring how AI can reshape the understanding of rare genetic…

Read the analysis

Archive

The record behind the point of view.

Historical perspectives, organised by their original publication date, form the record behind Lonrú’s point of view.

2026

32 articles

5 August 2026

AI and governed systems

The Valuation Engine: Defending Asset Worth with Dynamic Intelligence

Read

29 July 2026

AI and governed systems

Frictionless Due Diligence: The Automated Data Room

Read

24 July 2026

AI and governed systems

The $50k Compute Catalyst: What Anthropic’s Rare Disease Grants Actually Signal

Read

22 July 2026

AI and governed systems

Structuring IP for Modern Discovery

Read

15 July 2026

Capital and partnering

Prepare Academic Portfolios for Better Partner Conversations

Read

8 July 2026

Regulation and operations

The Wedge Opportunity: Time-to-Market and Compliance

Read

1 July 2026

AI and governed systems

Show How Your Technology Supports Scale, Not Just Efficacy

Read

24 June 2026

Cell and gene therapy

The Scaling Divide: Target the Bottleneck, Not Just the Modality

Read

18 June 2026

AI and governed systems

The Final Mile: Translating Science to Scale

Read

10 June 2026

AI and governed systems

Human Review Is Part of the Architecture

Read

3 June 2026

AI and governed systems

Design an AI Quality Layer People Can Trust

Read

27 May 2026

AI and governed systems

Protect Proprietary Data Before It Enters an AI Workflow

Read

20 May 2026

AI and governed systems

Designing a Safer Path for Proprietary Data

Read

6 May 2026

AI and governed systems

Give Senior Specialists More Time for Decisions

Read

29 April 2026

AI and governed systems

Test an AI Workflow Before It Reaches the Work That Matters

Read

22 April 2026

AI and governed systems

Why Your Autonomous AI Will Fail Audit: The Case for the 'Site Inspector'

Read

15 April 2026

AI and governed systems

Give AI Tools Clear Boundaries and Accountable Oversight

Read

8 April 2026

AI and governed systems

Build the Data Foundation Before You Scale the Workflow

Read

1 April 2026

AI and governed systems

Why an AI Pilot Needs a Working Operating Model

Read

25 March 2026

Regulation and operations

Strategy Needs an Operating Path

Read

18 March 2026

Regulation and operations

Deploying a CGT is Hard Enough. Why Are Hospitals Still Tracking Patient Journeys on Disparate Tools?

Read

16 March 2026

AI and governed systems

Accelerating DIY with AI - A Lonrú Lens Side Quest for the Gemini Live Agent Challenge

Read

11 March 2026

Capital and partnering

The End of the Vanity Facility: Why CGT Manufacturing Strategy Requires Active Architecture.

Read

4 March 2026

Capital and partnering

Effective Due Diligence Requires Active Architecture.

Read

25 February 2026

Capital and partnering

Compare Spin-Out and Licensing Paths With the Right Evidence

Read

18 February 2026

Regulation and operations

Stop Pitching Features. Start Calculating COGS: The B2B Sales Engine for Bioprocessing.

Read

11 February 2026

Regulation and operations

Beyond the Report: a Dynamic View of UK Cell and Gene Therapy Clinical Trials

Read

4 February 2026

Capital and partnering

The Cost of Yes: Why Strategic Dilution is Killing Your Innovation Pipeline

Read

28 January 2026

Cell and gene therapy

Beyond the Repository: Transforming Contracts into Active Risk Intelligence

Read

21 January 2026

Commercial strategy

When a Workflow Needs More Than Alignment

Read

14 January 2026

Capital and partnering

Operational Latency: Solving the Structural Gap Between Strategy and Execution

Read

7 January 2026

AI and governed systems

Escaping AI Pilot Purgatory: Why 2025 Was the Year of the Builder

Read

2025

41 articles

25 November 2025

Cell and gene therapy

Talking Turkey: How CGT-Enabling Technologies Could Strengthen Future Biosecurity

Read

18 November 2025

Regulation and operations

Are You Post-Approval Ready? What the FDA’s New Guidance Means for CGT Enabling Technology Providers

Read

5 November 2025

Capital and partnering

How Public-Private Partnerships Are Shaping Global Cell & Gene Therapy

Read

29 October 2025

Regulation and operations

From Europe’s Evidence Framework to the U.S. Commercial Opportunity in CGT

Read

22 October 2025

Regulation and operations

Mapping the Approval Landscape of Europe’s Cell & Gene Therapies

Read

16 October 2025

Regulation and operations

How Advanced Therapy Treatment Centre Networks Enable National Delivery of Cell and Gene Therapies

Read

8 October 2025

Regulation and operations

Europe’s Next Translation: Mapping the Networks Behind Cell and Gene Therapy

Read

1 October 2025

Capital and partnering

2025 Investment Signal Heatmap: A Snapshot of Cell and Gene Therapy

Read

24 September 2025

Regulation and operations

RNA x Cell and Gene Therapy: exploring the Intersections

Read

17 September 2025

Regulation and operations

Ireland’s Cell and Gene Therapy Map: Illuminating the Island’s Growing Ecosystem

Read

10 September 2025

Regulation and operations

CRISPR Clinical Trials: Global Shifts and New Directions

Read

3 September 2025

Regulation and operations

The Arc of Innovation in Cell & Gene Therapy: A Decade of Milestones and Signals Ahead

Read

27 August 2025

Regulation and operations

A Whistle-Stop Tour Around the Cell And Gene Therapy World

Read

20 August 2025

Regulation and operations

The Business of Reaching Patients: ESGCT 2025 Preview

Read

13 August 2025

Regulation and operations

CRISPR Safety: Where Tools Companies Can Lead

Read

6 August 2025

Regulation and operations

A global view on point of care manufacturing regulations after the UK’s leap

Read

30 July 2025

Regulation and operations

MHRA’s Point‑of‑Care Manufacturing Framework

Read

22 July 2025

Capital and partnering

Beyond NPV: Quantifying Patient Benefit in Cell & Gene Therapies

Read

16 July 2025

Cell and gene therapy

Bridging The Data Gap On The Pediatric CRISPR Highway

Read

9 July 2025

Cell and gene therapy

Who Follows Verve?

Read

1 July 2025

Regulation and operations

From Pipeline Fillers to Platform Plays

Read

25 June 2025

Capital and partnering

The Non-Viral Delivery Surge: LNPs, Extracellular Vesicles & the Emerging Pipeline in Cell & Gene Therapy

Read

11 June 2025

Regulation and operations

From Bottleneck to Backbone: Building the U.S. “Interventional-Genetics Interstate”

Read

17 May 2025

Cell and gene therapy

Reflections from ASGCT 2025

Read

13 May 2025

Capital and partnering

How patient-led business models are accelerating the next wave of cell & gene therapies

Read

8 May 2025

Regulation and operations

Through the Lonrú Lens to What to Watch at ASGCT 2025

Read

23 April 2025

AI and governed systems

Meeting on the Med: a pulse check on CGT

Read

2 April 2025

Cell and gene therapy

Unlocking Cell and Gene Therapies: Introducing VantagePoint™ to Lonrú Consulting’s Suite of Solutions For Growth

Read

26 March 2025

Cell and gene therapy

Navigating Strategic Partnerships: How Platform Technology Providers Can Overcome Validation Challenges

Read

19 March 2025

Regulation and operations

Catalysing the COGs Revolution: The Role of Enabling Technologies in CGT

Read

12 March 2025

Regulation and operations

Illuminating CRISPR Clinical Trial Progress: A Lonrú Lens for Enabling Tools Providers

Read

5 March 2025

Regulation and operations

Bridging the Gap, Enabling Technology Providers & the Path to the Clinic

Read

26 February 2025

Regulation and operations

Lonrú at Keystone: Precision Genome Engineering and the Future of CRISPR Clinical Translation

Read

19 February 2025

Capital and partnering

How the Focus of Cell and Gene Clinical Trials in the UK is Shifting

Read

11 February 2025

Cell and gene therapy

Academic Translational Centres Need More Than Great Science

Read

5 February 2025

AI and governed systems

Building an All-Island CGT Strategy: Ireland’s Opportunity to Deliver Cell and Gene Therapy

Read

28 January 2025

Capital and partnering

De-risking Cell and Gene Therapy Development: Global Regulatory Strategies for Streamlined Development

Read

23 January 2025

Capital and partnering

What Advanced Therapies Can Learn From Precision Manufacturing

Read

14 January 2025

Capital and partnering

Illuminating the Future of Cell and Gene Therapies

Read

13 January 2025

Capital and partnering

Charting the Trajectory of Cell and Gene Therapy from 2024 to 2025

Read

8 January 2025

Regulation and operations

Introducing Lonrú Consulting

Read

Have a question behind the question?

Bring the signal into a working session.

We can help connect the evidence to the decision surface that matters.

Start a conversation